The comparison of effects of two drugs in neutropenic patients
Phase 3
- Conditions
- eutropenia.Neutropenia
- Registration Number
- IRCT2017011131878N1
- Lead Sponsor
- Vice chancellor for research, Arak University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 90
Inclusion Criteria
Solid tumor confirmed by pathology; Children less than 15 years; Parental consent.
Exclusion criteria: Severe infection; Use of Corticosteroid; Sensitivity to filgrastim or pegfilgrastim; Lack of parental consent to continue participating in the study.
Exclusion Criteria
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Absolute Neutrophil Count. Timepoint: Before chemotherapy and the first, third, seventh and fourteenth day after Granulocyte Colony Stimulating Factor (GCSF) administration. Method of measurement: Laboratory.
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What are the molecular mechanisms of filgrastim and pegfilgrastim in managing chemotherapy-induced neutropenia in pediatric oncology?
How does pegfilgrastim compare to filgrastim in reducing febrile neutropenia incidence in children with solid tumors undergoing chemotherapy?
Which biomarkers are associated with differential response to filgrastim versus pegfilgrastim in neutropenic pediatric cancer patients?
What are the adverse event profiles and management strategies for filgrastim and pegfilgrastim in pediatric chemotherapy settings?
Are there combination therapies or alternative drugs showing better efficacy than filgrastim or pegfilgrastim in treating chemotherapy-induced neutropenia in children?